Abstract
Purpose
The prevalence of Group B Streptococcus (GBS) colonization in pregnant Korean women is increasing; however, nationwide studies are lacking. Therefore, we aimed to analyze regional colonization rates and antimicrobial susceptibility for GBS in pregnant Korean women through a nationwide survey.
Materials and Methods
From January 2018 to December 2020, data from the Seoul Clinical Laboratories on vaginal swab cultures were retrospectively analyzed to detect maternal GBS carriers. Each swab specimen was inoculated onto a 5% blood agar plate and incubated at 35℃–37℃ in a 5% CO2 incubator for 24 h. GBS isolates were identified using a Microflex MALDI Biotyper. Antimicrobial susceptibility tests were performed using the Vitek 2 automated system.
Results
The overall nationwide GBS colonization rate in pregnant Korean women was found to be 10.6% (3578/33721). The maternal GBS colonization rates ranged from 10.5%–10.8% over the 3-year study period. The GBS colonization rates by province, in descending order, were as follows: Jeolla-do, 13.2%; Gangwon-do, 12.0%; Chungcheong-do, 11.8%; Gyeonggi-do, 11.3%; Seoul, 10.2%; and Gyeongsang-do, 9.6%. During the study period, the resistance rates against chloramphenicol, levofloxacin, clindamycin, erythromycin, and tetracycline were 2.6%–2.7%, 18.2%–19.6%, 33.4%–35.7%, 35.6%–36.8%, and 50.5%–53.3%, respectively.
Conclusion
In pregnant Korean women, GBS colonization rates were in the range of 9.6%–13.2%, with Gyeongsang-do being the lowest and Jeolla-do the highest. The resistance rate against clindamycin was high (33.4%–35.7%). GBS colonization rates during pregnancy should be studied nationwide according to the Centers for Disease Control and Prevention-recommended guidelines with periodic antimicrobial resistance monitoring.
Keywords: Group B Streptococcus, pregnant women, erythromycin, clindamycin
INTRODUCTION
Group B Streptococcus (GBS) is the primary cause of neonatal bacterial infections, including sepsis, pneumonia, and meningitis, which can lead to death or long-term effects.1,2 GBS infections can present from birth to day 6 [early onset disease (EOD)] or from day 7 to day 89 (late-onset disease). The primary risk factor for neonatal GBS EOD is the colonization of maternal genitourinary and gastrointestinal tracts. Approximately 50% of women who are colonized with GBS can transmit the bacteria to their newborns.3 Vertical transmission usually occurs during labor or after membrane rupture. Implementation of the United States national guidelines for intrapartum antibiotic prophylaxis has resulted in a reduction of >80% in the incidence of GBS EOD, from 1.8 newborns per 1000 live births in the 1990s to 0.23 newborns per 1000 live births in 2015.4 In the absence of intrapartum antibiotic prophylaxis, 1%–2% of the newborns can develop GBS EOD.3
The key obstetric measures necessary for effective prevention of GBS EOD include universal prenatal screening using vaginal–rectal culture, correct specimen collection and processing, appropriate implementation of intrapartum antibiotic prophylaxis, and coordination with pediatric care providers.3 Other factors that influence the incidence rate of GBS EOD are strain virulence, inoculum size, premature or prolonged membrane rupture, preterm delivery, maternal bacteriuria, and serum concentrations of immunoglobulin G antibodies specific for the colonizing capsular polysaccharide type.5
The GBS colonization rate in pregnant women varies not only by country and race but also by the study period. In the past, the GBS colonization rate in pregnant Korean women was known to be lower than that in pregnant women from Western countries; however, its prevalence has been increasing recently.6,7 According to a single medical institution’s longitudinal studies, the colonization rates of GBS in pregnant Korean women were 3.9% in 1993,8 5.9% in 1995,9 11.5% in 2008–2009,10 and 19.8% in 2017–2019.7 Moreover, an abundance of serotype III and V GBS isolates with multi-drug resistance to clindamycin, erythromycin, and tetracycline has been rapidly increasing in Korea, thus narrowing the choice of therapeutic agents available against infections caused by these serotypes.7,11,12 However, there has been no nationwide survey on the colonization rate of GBS in pregnant Korean women or antimicrobial susceptibility testing of GBS isolated from pregnant Korean women. Therefore, this study retrospectively analyzed the regional colonization rate and antimicrobial susceptibility results of GBS in pregnant Korean women using data obtained from national network hospitals of Seoul Clinical Laboratories.
MATERIALS AND METHODS
Data collection
From January 2018 to December 2020, 33721 vaginal swab samples collected at obstetrics and gynecology specialized hospitals and obstetrics and gynecology clinics in general hospitals across South Korea were referred to Seoul Clinical Laboratories for GBS culture. All swabs were immediately placed in Stuart transport medium (Becton Dickinson, Sparks, MD, USA). Of the 33721 women attending a hospital for antenatal care, including GBS screening, 90% of the pregnant women were 25–38 years old (mean: 32.0 years; range: 14–48 years). Sample size determination is an important factor when attempting to compare and confirm the colonization rate in retrospective studies, wherein the tested number of populations may be different. If the study population is small, there is a possibility that the colonization rate is incorrectly evaluated as very low or high. The minimum sample size is determined using Slovin’s formula as follows:
n=N/(1+N(e)2)13
where n is the sample size, N is the population size, and e is the margin of error. Adequate sample size calculation in prevalence studies can be determined using the formula n=Z2P (1-P)/d2 (n=sample size, Z=the statistic corresponding to level of confidence, P=expected prevalence, and d=precision).14 However, it is difficult to ascertain the population size of pregnant women at 35–37 gestational weeks by region in a retrospective survey.
Statistical analysis
The statistical significance of differences in colonization rate by year, and region was analyzed using chi-square tests. All probability values were two-sided, and p values less than 0.05 were considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics v. 25.0 (IBM Corp., Armonk, NY, USA).
Culture and identification methods for GBS
Each swab specimen was inoculated on a 5% blood agar plate (Synergy Innovation, Seongnam, Korea) and incubated at 35℃–37℃ in a 5% CO2 incubator for 24 h. For GBS detection, suspicious colonies showing large, gray, and translucent colonies with a narrow zone of beta-hemolysis or non-beta-hemolysis on blood agar plates were identified using a Microflex MALDI Biotyper (Bruker Daltonik GmbH, Bremen, Germany). A total of 3512 GBS isolates was tested for antimicrobial susceptibility to ampicillin, penicillin, cefotaxime, ceftriaxone, cefepime, meropenem, levofloxacin, erythromycin, clindamycin, tetracycline, chloramphenicol, and vancomycin using the Vitek 2 automated system (bioMérieux, Marcy l’Etoile, France).15
Ethical approval
Seoul Clinical Laboratories (approval no. IRB-21-057-01) approved this study and stated that a written informed consent was not required.
RESULTS
Colonization rate
The overall GBS colonization rate in pregnant Korean women was 10.6% (3578/33721). There was no difference in the maternal GBS colonization rates by year, with rates of 10.8%, 10.5%, and 10.5% in 2018, 2019, and 2020, respectively.
The maternal colonization rates of GBS by region, in descending order, were 13.2%, 12.0%, 11.8%, 11.3%, 10.2%, and 9.6% in Jeolla-do, Gangwon-do, Chungcheong-do, Gyeonggi-do, Seoul, and Gyeongsang-do, respectively (Table 1). The differences in colonization rates by year in Seoul (p=0.114), Gyeonggi-do (p=0.632), Gangwon-do (p=0.117), Chungcheong-do (p=0.358), Gyeongsang-do (p=0.665), and Jeolla-do (p=0.383) were not significantly different. The differences in colonization rates by region were as follows: Gangwon-do and Jeolla-do had high positivity rates in 2018 (p<0.01), Seoul and Gyeongsang-do had low positivity rates in 2019 (p<0.01), and there was no statistically significant difference in 2020 (p>0.05). Fig. 1 shows the rate of maternal colonization in regional cities, obtained with more than 30 culture samples.
Table 1. Colonization Rate of Group B Streptococcus Isolates in Pregnant Women according to a Korean Nationwide Survey during 2018–2020.
| Province | City | Number (%) of isolates/Number of cultured samples, year | |||
|---|---|---|---|---|---|
| 2018 | 2019 | 2020 | Total | ||
| Seoul | 143 (11.4)/1255 | 72 (8.6)/839 | 68 (10.1)/672 | 283 (10.2)/2766 | |
| Gyeonggi-do | Paju | 56 (13.6)/413 | 56 (13.6)/413 | ||
| Ilsan | 92 (13.3)/693 | 111 (13.9)/799 | 97 (11.8)/824 | 300 (13.0)/2316 | |
| Gimpo | 22 (6.6)/331 | 21 (6.2)/340 | 23 (6.4)/359 | 66 (6.4)/1030 | |
| Incheon | 54 (13.4)/403 | 14 (18.4)/76 | 0 (0.0)/2 | 68 (14.1)/481 | |
| Bucheon | 4 (8.0)/50 | 0 (0.0)/12 | 38 (10.9)/348 | 42 (10.2)/410 | |
| Seongnam | 111 (10.2)/1085 | 116 (12.0)/966 | 105 (11.0)/953 | 332 (11.1)/3004 | |
| Suwon | 192 (11.7)/1646 | 200 (11.3)/1776 | 177 (10.9)/1618 | 569 (11.3)/5040 | |
| Subtotal | 475 (11.3)/4208 | 462 (11.6)/3969 | 496 (11.0)/4517 | 1433 (11.3)/12694 | |
| Gangwon-do | Chuncheon | 8 (6.6)/121 | 8 (6.6)/121 | ||
| Gangneung | 16 (17.2)/93 | 7 (10.8)/65 | 7 (10.4)/67 | 30 (13.3)/225 | |
| Wonju | 12 (15.8)/76 | 49 (12.0)/407 | 45 (12.0)/374 | 106 (12.4)/857 | |
| Subtotal | 28 (16.6)/169 | 56 (11.9)/472 | 60 (10.7)/562 | 144 (12.0)/1203 | |
| Chungcheong-do | Cheonan | 15 (10.4)/144 | 101 (12.6)/799 | 80 (12.0)/665 | 196 (12.2)/1608 |
| Sejong | 9 (7.8)/115 | 24 (11.8)/204 | 9 (10.7)/84 | 42 (10.4)/403 | |
| Daejeon | 2 (6.5)/31 | 2 (6.5)/31 | |||
| Subtotal | 26 (9.0)/290 | 125 (12.5)/1003 | 89 (11.9)/749 | 240 (11.8)/2042 | |
| Gyeongsang-do | Sangju | 0 (0.0)/11 | 0 (0.0)/7 | 0 (0.0)/18 | |
| Gimcheon | 0 (0.0)/11 | 0 (0.0)/11 | |||
| Gumi | 0 (0.0)/1 | 22 (9.6)/230 | 22 (9.5)/231 | ||
| Daegu | 0 (0.0)/14 | 0 (0.0)/9 | 4 (10.5)/38 | 4 (6.6)/61 | |
| Pohang | 100 (12.9)/774 | 59 (8.8)/672 | 79 (11.2)/708 | 238 (11.0)/2154 | |
| Gyeongju | 5 (14.7)/34 | 3 (25.0)/12 | 8 (17.4)/46 | ||
| Gimhae | 84 (14.2)/593 | 78 (11.6)/670 | 66 (9.7)/682 | 228 (11.7)/1945 | |
| Busan | 264 (8.2)/3228 | 284 (8.9)/3202 | 290 (9.5)/3060 | 838 (8.8)/9490 | |
| Jinju | 0 (0.0)/1 | 0 (0.0)/1 | 0 (0.0)/2 | ||
| Subtotal | 453 (9.8)/4644 | 424 (9.3)/4577 | 461 (9.7)/4737 | 1338 (9.6)/13958 | |
| Jeolla-do | Jeonju | 53 (16.0)/332 | 39 (12.5)/311 | 37 (13.3)/278 | 129 (14.0)/921 |
| Gwangju | 5 (10.6)/47 | 3 (8.1)/37 | 2 (5.1)/39 | 10 (8.1)/123 | |
| Jeongeup | 1 (9.1)/11 | 0 (0.0)/3 | 1 (7.1)/14 | ||
| Subtotal | 59 (15.1)/390 | 42 (12.0)/351 | 39 (12.3)/317 | 140 (13.2)/1058 | |
| Sum | 1184 (10.8)/10956 | 1181 (10.5)/11211 | 1213 (10.5)/11554 | 3578 (10.6)/33721 | |
Fig. 1. Rate of maternal colonization in regional cities in which more than 30 culture samples were obtained.
Antimicrobial susceptibility
All GBS isolates were susceptible to ampicillin, penicillin, vancomycin, ceftriaxone, cefotaxime, cefepime, and meropenem. The minimal inhibitory concentrations (MICs) of penicillin against GBS isolates were ≤0.06 µg/mL and 0.12 µg/mL in 71.3% and 28.78% of the isolates, respectively, and the MICs of ampicillin were ≤0.25 µg/mL. Among the 1672 strains for which the chloramphenicol antimicrobial susceptibility test was performed, the proportion of multidrug-resistant GBS isolates with resistance to three or more antibiotic agents of different classes was 32.2% (Table 2).
Table 2. Resistance Patterns of 538 Multi-Drug Resistant Group B Streptococcus Isolates among 1672 GBS Isolates.
| Susceptibility to antimicrobial agents | n | ||||
|---|---|---|---|---|---|
| Chloramphenicol | Levofloxacin | Clindamycin | Erythromycin | Tetracycline | |
| S | S | R | R | R | 364 |
| S | R | R | R | R | 110 |
| S | R | R | R | S | 14 |
| S | R | S | R | R | 7 |
| S | R | I | R | R | 1 |
| S | R | R | R | S | 1 |
| S | I | R | R | R | 2 |
| R | R | R | R | R | 23 |
| R | R | R | R | S | 1 |
| R | R | S | R | R | 2 |
| R | S | R | R | R | 7 |
| R | S | R | R | S | 2 |
| R | S | S | R | R | 2 |
| R | I | R | R | R | 2 |
S, susceptible; R, resistant; I, intermediate.
The resistance rates against non-beta-lactam agents were as follows: chloramphenicol (2.6%–2.7%), levofloxacin (18.2%–19.6%), clindamycin (33.4%–35.7%), erythromycin (35.6%–36.8%), and tetracycline (50.0%–53.3%). There were no statistically significant differences in resistance rates by year (p value; chloramphenicol 0.753, levofloxacin 0.659, clindamycin 0.593, erythromycin 0.876, tetracycline 0.301). The regions with consistently higher resistance rates against non-beta-lactam agents than the national average resistance rate over the 3-year study period were as follows: tetracycline, Chungcheong-do, Gyeonggi-do, and Gangwon-do; erythromycin, Seoul, Gangwon-do, and Chungcheong-do; clindamycin, Gyeonggi-do, Gangwon-do, and Chungcheong-do; and levofloxacin, Seoul, Gyeonggi-do, and Chungcheong-do (Table 3).
Table 3. Antimicrobial Susceptibility of Group B Streptococcus in Pregnant Women according to a Korean Nationwide Survey during 2018–2020.
| Province | City | Antimicrobial resistance rate by years, %* | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chloramphenicol | Levofloxacin | Clindamycin | Erythromycin | Tetracycline | ||||||||||||
| 2018 | 2019 | 2020 | 2018 | 2019 | 2020 | 2018 | 2019 | 2020 | 2018 | 2019 | 2020 | 2018 | 2019 | 2020 | ||
| Seoul | - | 3.2 | 1.5 | 21.0143 | 20.872 | 20.668 | 42.7 | 41.7 | 32.4 | 45.5 | 40.3 | 38.2 | 56.6 | 51.4 | 52.9 | |
| Gyeonggi-do | Paju | - | ND | 5.4 | ND | ND | 21.456 | ND | ND | 35.7 | ND | ND | 37.5 | ND | ND | 66.1 |
| Ilsan | - | 2.6 | 3.1 | 17.492 | 18.0111 | 21.697 | 39.1 | 35.1 | 39.2 | 39.1 | 35.1 | 40.2 | 52.2 | 59.5 | 54.6 | |
| Gimpo | - | 0.0 | 0.0 | 22.722 | 38.121 | 21.723 | 27.3 | 47.6 | 43.5 | 31.8 | 57.1 | 39.1 | 59.1 | 52.4 | 56.5 | |
| Incheon | - | 0.0 | ND | 22.254 | 14.314 | ND | 38.9 | 28.6 | ND | 42.6 | 28.6 | ND | 70.4 | 64.3 | ND | |
| Bucheon | - | ND | 0.0 | 0.04 | ND | 23.738 | 25.0 | ND | 23.7 | 50.0 | ND | 21.1 | 25.0 | ND | 39.5 | |
| Seongnam | - | 7.1 | 1.0 | 15.3111 | 24.1116 | 19.0105 | 39.6 | 33.6 | 35.2 | 42.3 | 38.8 | 34.3 | 61.3 | 53.4 | 59.0 | |
| Suwon | - | 4.3 | 3.4 | 22.4192 | 22.5200 | 18.1177 | 37.5 | 39.5 | 37.9 | 37.5 | 42.0 | 36.7 | 50.0 | 57.0 | 56.5 | |
| Subtotal | - | 4.2 | 2.6 | 19.6475 | 22.3462 | 20.0496 | 37.9 | 37.0 | 36.5 | 39.4 | 39.8 | 35.9 | 55.6 | 56.7 | 56.5 | |
| Gangwon-do | Chuncheon | - | ND | 12.58 | ND | ND | 37.58 | ND | ND | 50.0 | ND | ND | 50.0 | ND | ND | 50.0 |
| Gangneung | - | 0.0 | 0.07 | 25.016 | 14.37 | 0.07 | 50.0 | 42.9 | 14.3 | 43.8 | 42.9 | 14.3 | 62.5 | 42.9 | 42.9 | |
| Wonju | - | 0.0 | 2.245 | 33.312 | 14.349 | 11.145 | 33.3 | 46.9 | 48.9 | 33.3 | 44.9 | 48.9 | 41.7 | 63.3 | 60.0 | |
| Subtotal | - | 0.0 | 3.360 | 28.628 | 14.356 | 13.360 | 42.9 | 46.4 | 45.0 | 39.3 | 44.6 | 45.0 | 53.6 | 60.7 | 56.7 | |
| Chungcheong-do | Cheonan | - | 3.1 | 5.0 | 20.015 | 25.7101 | 25.080 | 40.0 | 33.7 | 42.5 | 46.7 | 37.6 | 42.5 | 73.3 | 51.5 | 62.5 |
| Sejong | - | 0.0 | 0.0 | 11.19 | 20.824 | 22.29 | 33.3 | 41.7 | 33.3 | 33.3 | 37.5 | 44.4 | 55.6 | 70.8 | 55.6 | |
| Daejeon | - | ND | ND | 50.02 | ND | ND | 100.0 | ND | ND | 50.0 | ND | ND | 50.0 | ND | ND | |
| Subtotal | - | 2.6 | 4.5 | 19.226 | 24.8125 | 24.789 | 42.3 | 35.2 | 41.6 | 42.3 | 37.6 | 42.7 | 65.4 | 55.2 | 61.8 | |
| Gumi | - | ND | 4.5 | ND | ND | 18.222 | ND | ND | 36.4 | ND | ND | 40.9 | ND | ND | 54.5 | |
| Daegu | - | ND | 0.0 | ND | ND | 25.04 | ND | ND | 50.0 | ND | ND | 50.0 | ND | ND | 75.0 | |
| Gyeongsang-do | Pohang | - | 4.2 | 0.0 | 16.0100 | 13.659 | 17.779 | 31.0 | 28.8 | 39.2 | 36.0 | 32.2 | 40.5 | 52.0 | 40.7 | 50.6 |
| Gyeongju | - | 0.0 | ND | 20.05 | 33.33 | ND | 20.0 | 100.0 | ND | 20.0 | 66.7 | ND | 40.0 | 100.0 | ND | |
| Gimhae | - | 2.9 | 6.1 | 15.584 | 12.878 | 22.766 | 25.0 | 24.4 | 36.4 | 28.6 | 21.8 | 40.9 | 45.2 | 38.5 | 56.1 | |
| Busan | - | 2.9 | 2.4 | 15.9264 | 13.0284 | 18.6290 | 26.9 | 26.4 | 31.7 | 30.3 | 31.3 | 33.1 | 39.0 | 41.2 | 44.5 | |
| Subtotal | - | 3.1 | 2.6 | 15.9453 | 13.2424 | 19.1461 | 27.4 | 26.9 | 34.1 | 31.1 | 30.0 | 36.0 | 43.0 | 41.0 | 47.9 | |
| Jeolla-do | Jeonju | - | 0.0 | 0.0 | 15.153 | 15.439 | 18.937 | 32.1 | 17.9 | 21.6 | 30.2 | 20.5 | 27.0 | 43.4 | 35.9 | 51.4 |
| Gwangju | - | 0.0 | 0.0 | 0.05 | 0.03 | 0.02 | 20.0 | 66.7 | 50.0 | 20.0 | 33.3 | 50.0 | 40.0 | 33.3 | 100.0 | |
| Jeongeup | - | ND | ND | 0.01 | ND | ND | 0.0 | ND | ND | 100.0 | ND | ND | 0.0 | ND | ND | |
| Subtotal | - | 0.0 | 0.0 | 13.659 | 14.342 | 17.939 | 30.5 | 21.4 | 23.1 | 30.5 | 21.4 | 28.2 | 42.4 | 35.7 | 53.8 | |
| Sum | - | 2.7 | 2.6 | 18.21184 | 18.51181 | 19.61213 | 34.3 | 33.4 | 35.7 | 36.6 | 35.6 | 36.8 | 50.4 | 50.0 | 53.3 | |
ND, not done.
*Number of isolates tested.
DISCUSSION
The GBS colonization rates among pregnant Korean women ranged from 1.96%–19.8%, and the colonization rate varied depending on the culture medium used, the site of sample collection, and the number of participants.6,7,16 The US Centers for Disease Control and Prevention (CDC) recommends the use of Todd Hewitt Broth with gentamicin and nalidixic acid (or Lim Broth) to maximize the likelihood of recovering group B streptococci upon plating on sheep blood agar.17 Swabbing both the lower vagina and rectum (through the anal sphincter) increases the culture yield substantially compared with that obtained by sampling the cervix or the vagina without swabbing the rectum.17 When direct agar plating is used instead of selective enrichment broth, as many as 50% of women who are GBS carriers show false-negative culture results.17 Accordingly, the colonization rate in the current study would be lower than that obtained when the CDC recommended protocol17 is applied, because the vaginal samples were directly inoculated on sheep blood agar without preincubation with the GBS selective enrichment broth.
Recently, it has been reported that non-beta-hemolytic GBS (NH-GBS) are present in approximately 3.5%–8% of all GBS strains from humans.7,18 In this study, the proportion of NH-GBS could not be accurately evaluated because colonies suspected of GBS were selected based only on the characteristics of colonies in blood agar. In previous Korean studies, the proportion of NH-GBS was reported to be 4.7%19 and 8.0%.7 Although NH-GBS strains were reported to be approximately four times more frequently associated with noninvasive diseases or colonization than with invasive infections, 71% of the NH-GBS strains from adult invasive infections were from bacteremia.18 Both animals and humans constitute natural reservoirs for GBS, but knowledge regarding the host specificity of this bacterium is sparse.20 A striking biochemical difference between the isolates obtained from humans and cattle is their ability to ferment lactose.21 Duarte, et al.22 reported that 47.1% (n=85) of bovine GBS isolates showed non-beta-hemolysis with 100% lactose fermentation. NH-GBS isolates do not show an orange pigment in Granada medium, owing to the direct genetic linkage between orange pigment production and hemolysin production in GBS.7 Therefore, if a laboratorian identifies only beta-hemolytic colonies on blood agar media or yellow colonies on Granada media when detecting GBS carriers, the GBS colonization rate obtained may be lower than the actual value.
Considering that there was no change in the colonization rate in the recent 3 years in this nationwide survey, we suspect that a certain level of colonization has been reached and maintained in pregnant Korean woman. Moreover, the birth rate in Korea has continued to decline, suggesting a need for urgent action against the increasing rate of GBS infections in pregnant women. Accordingly, it is necessary to include GBS microbiological screening at 35–37 weeks of pregnancy in prenatal screening guidelines in Korea.
Although GBS isolates with reduced penicillin susceptibility have been reported in Korea, Japan, and the United States23,24 and penicillin non-susceptible GBS isolates have been reported in Ethiopia (11.1%),25 intravenous penicillin remains the agent of choice for intrapartum antibiotic prophylaxis, with intravenous ampicillin as an acceptable alternative. First-generation cephalosporins (i.e., cefazolin) are recommended for women whose reported penicillin allergy poses a low anaphylaxis risk or is of uncertain severity.3 In the current study, penicillin and ampicillin MIC levels were not reduced in all GBS isolates; however, periodic monitoring of the emergence of non-susceptible strains is required. For women with high penicillin anaphylaxis risk, clindamycin is the recommended alternative to penicillin, but only if the GBS isolate is susceptible to clindamycin.3 In the current study, the clindamycin resistance rate ranged from 33.4%–35.7%, which was higher than the 16.0% reported by Choi, et al.7 but lower than the 44.4% reported by Uh, et al.10 The clindamycin resistance rate of GBS has primarily been determined on the basis of the distribution of macrolide-lincosamide-streptogramin B (MLSB)-resistant phenotypes. GBS isolates with erm (TR)-mediated inducible MLSB resistance showed resistance to erythromycin and susceptibility to clindamycin; however, GBS isolates with inducible clindamycin resistance detected via disk diffusion using the D-zone test or broth microdilution should be reported as clindamycin resistant.13 Therefore, inducible clindamycin resistance detection should be performed in women with high beta-lactam antibiotic anaphylaxis risk. The multidrug-resistant GBS ratio of 32.2% obtained in this study was higher than the 18.9% reported by Safari, et al.26 and lower than the 35.2% reported by Leykun, et al.25 Most of the clindamycin-resistant GBS strains were also resistant to erythromycin and tetracycline. Accordingly, documentation on the detection of clindamycin resistance, including inducible resistance, should be included in the Korean guidelines for the prevention of perinatal GBS infection.
In conclusion, it is necessary to study the nationwide GBS colonization rate during pregnancy according to the recommended CDC guidelines.
ACKNOWLEDGEMENTS
This study was supported by a research grant from Seoul Clinical Laboratories.
Footnotes
The authors have no potential conflicts of interest to disclose.
- Conceptualization: Young-Jin Kim, Kyungwon Lee, and Young Uh.
- Data curation: Hye Gyung Bae, Jungmi Hong, and Young Uh.
- Formal analysis: Hye Gyung Bae and Young Uh.
- Investigation: Hye Gyung Bae.
- Methodology: Hye Gyung Bae.
- Project administration: Kyungwon Lee and Young-Jin Kim.
- Resources: Kyoung-Ryul Lee.
- Software: Hye Gyung Bae.
- Supervision: Kyoung-Ryul Lee, Kyungwon Lee, and Young Uh.
- Validation: Hye Gyung Bae, Seong Jin Choi, and Young Uh.
- Visualization: Young Uh.
- Writing—original draft: Hye Gyung Bae and Young Uh.
- Writing—review & editing: all authors.
- Approval of final manuscript: all authors.
References
- 1.Edwards MS, Nizet V, Baker CJ. In: Remington and Klein’s infectious diseases of the fetus and newborn infant. 8th ed. Wilson CB, Nizet V, Maldonado YA, Remington JS, Klein JO, editors. Philadelphia: Elsevier; 2016. Group B streptococcal infections; pp. 411–456. [Google Scholar]
- 2.Libster R, Edwards KM, Levent F, Edwards MS, Rench MA, Castagnini LA, et al. Long-term outcomes of group B streptococcal meningitis. Pediatrics. 2012;130:e8–e15. doi: 10.1542/peds.2011-3453. [DOI] [PubMed] [Google Scholar]
- 3.American College of Obstetricians and Gynecologists. Prevention of group B streptococcal early-onset disease in newborns: ACOG committee opinion summary, number 797. Obstet Gynecol. 2020;135:489–492. doi: 10.1097/AOG.0000000000003669. [DOI] [PubMed] [Google Scholar]
- 4.Nanduri SA, Petit S, Smelser C, Apostol M, Alden NB, Harrison LH, et al. Epidemiology of invasive early-onset and late-onset group B streptococcal disease in the United States, 2006 to 2015: multistate laboratory and population-based surveillance. JAMA Pediatr. 2019;173:224–233. doi: 10.1001/jamapediatrics.2018.4826. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Edwards MS, Baker CJ. In: Principles and practice of pediatric infectious diseases. 5th ed. Long SS, Prober CG, Fischer M, editors. Philadelphia: Elsevier; 2018. Streptococcus agalactiae (group B Streptococcus) pp. 723–735. [Google Scholar]
- 6.Kim DH, Min BJ, Jung EJ, Byun JM, Jeong DH, Lee KB, et al. Prevalence of group B Streptococcus colonization in pregnant women in a tertiary care center in Korea. Obstet Gynecol Sci. 2018;61:575–583. doi: 10.5468/ogs.2018.61.5.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Choi SJ, Kang J, Uh Y. Recent epidemiological changes in group B streptococcus among pregnant Korean women. Ann Lab Med. 2021;41:380–385. doi: 10.3343/alm.2021.41.4.380. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Uh Y, Kwon JY, Jang IH, Yoon KJ, Kim HG. Colonization rate of group B Streptococcus in pregnant women and neonates. Korean J Clin Pathol. 1994;14:447–453. [Google Scholar]
- 9.Uh Y, Jang IH, Yoon KJ, Lee CH, Kwon JY, Kim MC. Colonization rates and serotypes of group B streptococci isolated from pregnant women in a Korean tertiary hospital. Eur J Clin Microbiol Infect Dis. 1997;16:753–756. doi: 10.1007/BF01709259. [DOI] [PubMed] [Google Scholar]
- 10.Uh Y, Choi SJ, Jang IH, Lee KS, Cho HM, Kwon O, et al. Colonization rate, serotypes, and distributions of macrolide-lincosamide-streptograminB resistant types of group B streptococci in pregnant women. Korean J Clin Microbiol. 2009;12:174–179. [Google Scholar]
- 11.Uh Y, Jang IH, Hwang GY, Yoon KJ, Song W. Emerging erythromycin resistance among group B streptococci in Korea. Eur J Clin Microbiol Infect Dis. 2001;20:52–54. doi: 10.1007/s100960000414. [DOI] [PubMed] [Google Scholar]
- 12.Yoon IA, Jo DS, Cho EY, Choi EH, Lee HJ, Lee H. Clinical significance of serotype V among infants with invasive group B streptococcal infections in South Korea. Int J Infect Dis. 2015;38:136–140. doi: 10.1016/j.ijid.2015.05.017. [DOI] [PubMed] [Google Scholar]
- 13.Tejada JJ, Punzalan JRB. On the misuse of Slovin’s formula. Philipp Stat. 2012;61:129–136. [Google Scholar]
- 14.Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol Hepatol Bed Bench. 2013;6:14–17. [PMC free article] [PubMed] [Google Scholar]
- 15.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 29th ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2019. CLSI supplement M100. [Google Scholar]
- 16.Hong JS, Choi CW, Park KU, Kim SN, Lee HJ, Lee HR, et al. Genital group B streptococcus carrier rate and serotype distribution in Korean pregnant women: implications for group B streptococcal disease in Korean neonates. J Perinat Med. 2010;38:373–377. doi: 10.1515/jpm.2010.050. [DOI] [PubMed] [Google Scholar]
- 17.Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59:1–36. [PubMed] [Google Scholar]
- 18.Six A, Firon A, Plainvert C, Caplain C, Bouaboud A, Touak G, et al. Molecular characterization of nonhemolytic and nonpigmented group B streptococci responsible for human invasive infections. J Clin Microbiol. 2016;54:75–82. doi: 10.1128/JCM.02177-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Uh Y, Jang IH, Hwang GY, Yoon KJ. Serotypes and biochemical reaction patterns of group B streptococci. Korean J Clin Pathol. 1998;18:386–390. [Google Scholar]
- 20.Sørensen UBS, Klaas IC, Boes J, Farre M. The distribution of clones of Streptococcus agalactiae (group B streptococci) among herdspersons and dairy cows demonstrates lack of host specificity for some lineages. Vet Microbiol. 2019;235:71–79. doi: 10.1016/j.vetmic.2019.06.008. [DOI] [PubMed] [Google Scholar]
- 21.Sørensen UB, Poulsen K, Ghezzo C, Margarit I, Kilian M. Emergence and global dissemination of host-specific Streptococcus agalactiae clones. mBio. 2010;24:e00178-10. doi: 10.1128/mBio.00178-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Duarte RS, Miranda OP, Bellei BC, Brito MA, Teixeira LM. Phenotypic and molecular characteristics of Streptococcus agalactiae isolates recovered from milk of dairy cows in Brazil. J Clin Microbiol. 2004;42:4214–4222. doi: 10.1128/JCM.42.9.4214-4222.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Verani JR, McGee L, Schrag SJ Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC) Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59:1–36. [PubMed] [Google Scholar]
- 24.Yi A, Kim CK, Kimura K, Arakawa Y, Hur M, Yun YM, et al. First case in Korea of group B Streptococcus with reduced penicillin susceptibility harboring amino acid substitutions in penicillin-binding protein 2X. Ann Lab Med. 2019;39:414–416. doi: 10.3343/alm.2019.39.4.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Leykun Y, Genet C, Mulu W. Group B streptococci vaginal-recto colonization, vertical transmission to newborns, antimicrobial susceptibility profile and associated factors in selected health facilities of Bahir Dar city: a cross-sectional study. Infect Drug Resist. 2021;14:5457–5472. doi: 10.2147/IDR.S343429. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Safari D, Gultom SM, Tafroji W, Azzahidah A, Soesanti F, Khoeri MM, et al. Prevalence, serotype and antibiotic susceptibility of group B Streptococcus isolated from pregnant women in Jakarta, Indonesia. PLoS One. 2021;16:e0252328. doi: 10.1371/journal.pone.0252328. [DOI] [PMC free article] [PubMed] [Google Scholar]